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AMH – secretion and function
AMH (Anti-Müllerian Hormone, Müllerian 
Inhibiting Substance or Factor) is a dimeric glyco-
protein member of the transforming growth factor-β 
(TGF-β) family. In the male it is produced by the tes-
ticular Sertoli cells and its expression is initiated by 
the end of the 7th embryonic week. AMH causes re-
gression of the Müllerian ducts (derivatives of the 
uterus, fallopian tubes and upper part of the vagina) 
and thus plays an important role in shaping the male 
reproductive tract (1). The initiation of AMH secre-
tion is gonadotropin independent. Later AMH secre-
tion is up regulated by FSH and down regulated by 
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for the treatment of gynecological cancers and endometriosis.  
androgens. During fetal life and the first months af-
ter birth, when the levels of androgens are high, there 
is a physiological insensitivity of Sertoli cells to an-
drogens because of lack of androgen receptor expres-
sion in the Sertoli cells nuclei (2). The levels of AMH 
in males are high from the end of the 7th fetal week 
until the beginning of puberty, except for a transi-
tional decline in the perinatal period. With the on-
set of puberty AMH production is inhibited by the 
increase of intratesticular testosterone, which over-
comes the positive effect of FSH, and the onset of 
germ cell meiosis. Exogenous testosterone applica-
tions do not affect the AMH levels most probably be-
cause they do not lead to high intratesticular testos-
terone concentrations (1,2).
In the female AMH is produced by the gran-
ulosa cells of the pre antral and small antral ovari-
an follicles and may act to modulate the early stag-
es of follicular development by inhibiting the recruit-
ment of further primordial follicles into the growing 
pool and reducing the sensitivity of antral follicles to 
FSH (3). AMH production ceases rapidly when follic-
ular diameter reaches 8-10 mm (3,4). In a study per-
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formed in 804 healthy females at age ranging from 
infancy to the end of the reproductive period, Fong et 
al. found that AMH levels increase during childhood 
and reach a maximum at the age of 15.8 years, form a 
plateau until the age of 25 years and then start to de-
cline yearly at a consistent rate until below the clin-
ical detection limit by the age of 50 years or around 
5 years before menopause (5). AMH levels in women 
are a reliable marker for the ovarian reserve of pri-
mordial follicles. 
AMH - clinical use in the male
In the male AMH is a useful marker for the 
presence of testicular tissue in such cases as suspect-
ed anorchia, bilateral cryptorchidism or more com-
plex disorders of sex development (DSD) (6). Be-
tween 2nd – 6th month after birth (the so called “mini-
puberty”) the levels of gonadotropins and testoster-
one in boys are in the pubertal range but afterwards 
they normally decrease to undetectable values until 
the onset of puberty and cannot be used for evalua-
tion of the hypothalamo-pituitary-gonadal axis. On 
the contrary, during that period the Sertoli cells re-
main active and the determination of AMH is very 
useful without the need of performing stimulation 
tests (1).
46, XY DSD
Disorders of sex development (DSD) are de-
fined as congenital conditions in which development 
of chromosomal, gonadal and anatomical sex is atyp-
ical (7). Individuals with karyotype 46, XY have vari-
able levels of genital ambiguity, ranging from under-
virilized male to completely female external genita-
lia. In gonadal dysgenesis the fetal formation of the 
gonads is impaired. In the complete form the phe-
notype is female with normal external genitalia and 
preserved Müllerian structures while in the partial 
form the phenotype is variable, extending to normal 
male with infertility only. Several single gene disor-
ders (SRY, SF-1, WT1, SOX9, etc.) or chromosomal 
rearrangements have been described as causes for 
gonadal dysgenesis but currently genetic diagnosis 
could be reached in only around 30% of the cases (8). 
In accordance with the quite broad phenotyp-
ic spectrum of the gonadal dysgenesis the hormon-
al profiles show a variable reduction in AMH level. 
AMH is undetectable in anorchia and can be used 
to distinguish between that condition and bilateral 
cryptorchidism where it is in the normal range (6, 8). 
In conditions with impaired testosterone synthesis 
AMH is normal or high because of the lack of in-
hibitory effect of testosterone and the elevation of 
FSH, which up regulates AMH secretion (1). In an-
drogen insensitivity syndromes (AIS), mutations 
in the androgen receptor gene cause complete lack 
of virilization (complete androgen insensitivity syn-
drome, CAIS) and feminization of the external gen-
italia or partial undervirilisation (partial androgen 
insensitivity syndrome, PAIS) with genital ambigu-
ity. The testes differentiate normally. In newborns 
with CAIS, AMH is not as high as expected, prob-
ably because the levels of FSH remain low. In new-
borns with PAIS gonadotropins and AMH are ele-
vated. During childhood AMH remains within nor-
mal male range in both conditions. At puberty, in 
CAIS AMH is abnormally elevated for the high lev-
els of circulating testosterone. In PAIS intratesticular 
testosterone is capable of causing an incomplete in-
hibition of AMH, which is nonetheless inadequate-
ly high for the levels of circulating testosterone (1). 
The persistant Müllerian duct syndrome (PMDS) 
occurs due to mutations in the genes encoding AMH 
or its receptor (AMH receptor type II). In this con-
dition boys have normal male external genitalia but 
with persistent internal Müllerian structures. Pa-
tients with PMDS could be AMH-negative, with un-
detectable AMH levels indicative of AMH gene de-
fects or AMH-positive due to mutations in the AMH 
receptor gene or, in exceptional cases, mutations af-
fecting AMH bioactivity (6,8). 
Klinefelter syndrome (47, XXY)
Klinefelter syndrome and its variants (48, 
XXXY, etc.) is characterized by tall stature, gyneco-
mastia, small testes and hypergonadotropic hypogo-
nadism in late puberty and adulthood. The levels of 
AMH before puberty are normal but after puberty 
fall to subnormal values because of the progressive 
testicular degeneration. Thus AMH is a useful mark-
er for the testicular function in these patients (6).
Hypogonadotropic hypogonadism 
In infants with hypogonadotropic hypogonad-
ism AMH is low, while in boys with untreated central 
hypogonadism at pubertal age serum AMH is elevat-
ed for age, because of insufficient down regulation by 
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testosterone, but lower for the patient’s Tanner stage, 
because of lack of FSH stimulus (1).
Central precocious puberty 
Grinspon et al. found that in 6 untreated boys 
with central precocious puberty diagnosed at a me-
dian age of 3 years the AMH levels were low for their 
chronological age because the inhibitory effect of 
androgens on AMH secretion dominated over the 
stimulatory effect of FSH. During treatment with 
GnRH agonists AMH attained normal prepubertal 
values. The authors conclude that this could make 
AMH a useful marker for monitoring the efficacy of 
the treatment (9).
AMH – clinical use in the female  
In the female AMH is a clinically useful and 
more accurate than FSH marker for ovarian re-
serve. It is used for improvement of infertility treat-
ment, planning of pregnancies, menopause predic-
tion, monitoring of ovarian damage by medications 
and procedures, detection of PCOS (polycystic ovary 
syndrome) and POI (premature ovarian insufficien-
cy) (4). Recombinant AMH is a promising therapeu-
tic agent for treatment of gynecologic tumors and en-
dometriosis (10,11). 
Young cancer survivors 
In the last decades combined chemo- and radio-
therapy for malignancies in girls and young females 
has led to an improved survival rate and quality of 
life after anticancer treatment, including ovarian 
function and reproductive capacity, has become an 
important issue (12,13). Total body irradiation (TBI) 
or irradiation of the pelvic region and chemotherapy 
regiments including alkylating agents cause damage 
to ovarian follicles mainly by increased apoptosis. 
This damage can be permanent, leading to POI and 
infertility or in other cases, the ovarian function may 
recover. Follicular depletion may occur even if reg-
ular menstrual cycle has recovered (12). The Child-
hood Cancer Survivor Study (CCSS) has shown that 
premature menopause occurs in 8% of the cancer 
survivors and depends on age, dose of irradiation 
to the ovaries and the cumulative dose of the alkyl-
ating agents (14). With higher risk of impaired fer-
tility, more than 80% are patients after TBI, mega-
chemotherapy, irradiation for pelvic tumors, metat-
static soft tissue sarcomas and Hodgkin lymphomas 
treated with alkylating agents, independently of age 
at treatment (pre- or postpubertal). In these patients 
progressive lowering of AMH during treatment is 
observed without recovery after treatment, suggest-
ing a profound loss of the primordial follicle pool (13, 
15). Thus AMH is an early sensitive marker of re-
duced ovarian reserve in young cancer survivors.
Hyperandrogenism 
Polycystyc ovary syndrome (PCOS) affects ap-
proximately 6% of the women in reproductive age 
and results in menstrual disorders and infertility. 
The diagnostic criteria for PCOS are based on the 
2003 Rotterdam consensus and include: oligo- and/
or unovulation, clinical or biochemical hyperan-
drogenism and ultrasound findings of more than 12 
follicles with diameter of 2-9 mm, or ovarian volume 
of more than 10 cm3 (16). Levels of AMH in PCOS 
are 2-3 times higher than in normally ovulating and 
menstruating women and are positively correlated 
to the androgen level. They begin to decline 5 years 
later than in healthy women. Because AMH is not 
affected by the menstrual cycle or use of oral con-
traceptives it can be used as a biological marker for 
PCOS and the degree of impairment of folliculogen-
esis (17,16). In a study of 71 women with PCOS and 
71 controls at a reproductive age between 18 and 35 
years Wiweko et al. found that with a cutoff value of 
4.45 ng/ml, the serum AMH levels had a sensitivity 
of 76.1% and a specificity of 74.6% to predict PCOS. 
The mean levels of AMH were highest in the pheno-
types of unovulation, hyperandrogenism and poly-
cystic ovaries (16). Lin et al. obtained similar sensi-
tivity and specificity values, 70% and 76% respec-
tively, but at higher cutoff value of AMH – 7.3 ng/ml 
(18). Pawelczak et al. studied 23 adolescent females 
with PCOS (mean age 15.2±1.8 years) and 12 age and 
BMI matched controls (mean age 14.1±1.7 years) and 
found significantly higher AMH levels in the PCOS 
group (6.78±3.55 ng/ml vs 3.38±1.48 ng/ml). The au-
thors found also a positive correlation between AMH 
levels and ultrasound measured ovarian volume and 
concluded that AMH could supplement ultrasound 
in the clinical diagnosis and follow-up of PCOS (19). 
Granulosa cell tumors represent 2-5% of ovari-
an neoplasms and in prepubertal girls they may pres-
ent as precocious puberty. AMH is a reliable and spe-
cific marker of granulosa cells and their activity and 
is in the male concentrations range in such girls. Be-
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cause larger tumors gradually lose their AMH ex-
pression, there is an inverse correlation between the 
tumor size and the AMH level (6). Changes in AMH 
levels are also a marker for success of the treatment 
or recurrence of the tumor (10).
Diminished ovarian reserve 
In women with ovarian insufficiency serum 
AMH level is low and is the earliest and most ac-
curate serum marker for decline in ovarian reserve. 
Thus AMH may be the earliest clinical means of de-
tecting women at risk to develop POI or premature 
ovarian failure (POF) (4). 
In-vitro fertilization (IVF) 
Serum AMH concentration together with an-
tral follicular count (AFC) are among the best mark-
ers for predicting ovarian response to gonadotropin 
stimulation in IVF treatment. However, the value of 
AMH as a predicting tool for live-birth rate and oo-
cyte quality remains controversial (20,4). 
Gynecologic tumors and endometriosis 
It was first suggested by Professor Robert Scul-
ly, an expert in ovarian cancer from the Pathology 
Department of the Massachusetts General Hospital, 
that the ability of AMH to induce apoptosis and to 
inhibit cell division in a highly specific manner can 
be used for treatment of cancers of Müllerian duct 
origin. He proposed such treatment for epithelial 
ovarian cancers, which recapitulate embryonic Mül-
lerian histology (after 10). More recent experiments 
found that cervical and endometrial cancers, as well 
as some non-Müllerian cancers of the breast, prostate 
and ocular melanoma, could be a potential target for 
treatment with recombinant AMH because these tis-
sues express AMH type II receptors. Scientists pro-
pose initiation of phase I trials as soon as sufficient 
clinical material is available (10). In endometriosis 
there is implantation of endometrial glands and stro-
ma outside the uterine cavity, most commonly on 
the visceral and peritoneal surfaces, but also, though 
rarely, in the pleura, pericardium or brain. The prev-
alence of this condition in the general female popu-
lation is around 6-10%. It is usually associated with 
infertility, pelvic pain, dispareunia and though quite 
common, it is frequently misdiagnosed. The current 
treatment modalities, which include oral contracep-
tive pills, Danazol, gonadotropin releasing hormone 
analogues, progestins, androgens and surgical inter-
ventions have high recurrence rates of up to 45 % (21). 
Recent studies have found that AMH type II recep-
tors are expressed in the endometrium in the adult 
female where probably AMH in a paracrine fashion 
negatively regulates cellular viability (11). In experi-
mental in vitro models of endometriosis Signorile et 
al. found that AMH was able to inhibit cell prolif-
eration and induce apoptosis in endometriosis cells. 
This data suggests a possible use of AMH as treat-
ment for endometriosis but further studies are need-
ed (11).
CONCLUSIONS
AMH is a useful biomarker with important di-
agnostic and predictive value, both in the male and 
the female. Its use in the clinical practice is con-
stantly widening. AMH is also emerging as a prom-
ising therapeutic agent for treatment of cancers and 
endometriosis. 
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